Cloveit, 0.05% cream 25 g

GCS for external use.

Prevent marginal accumulation of neutrophils, decrease inflammatory exudation and production of lymphokines, inhibit macrophage migration, decrease the intensity of infiltration and granulation processes, have local anti-inflammatory, antipruritic, anti-allergic anti-exudative effects.

Indications

eczema (various forms);
psoriasis (except for pustular and extensive plaque psoriasis);
discoid lupus erythematosus;
lichen planus;
skin diseases resistant to therapy with less active corticosteroids for topical use.

Pharmacological effect

GKS for external use.

Prevents the marginal accumulation of neutrophils, reduces inflammatory exudation and the production of lymphokines, inhibits the migration of macrophages, reduces the intensity of infiltration and granulation processes, has local anti-inflammatory, antipruritic, antiallergic antiexudative effects.

Special instructions

Long-term use should be avoided. With long-term use over large areas of the skin, the frequency of side effects and the risk of edema, arterial hypertension, hyperglycemia, and decreased body resistance increases.

When clobetasol propionate is used externally, suppression of the pituitary-adrenal system is possible. This is expressed in a decrease in the production of ACTH by the pituitary gland, a decrease in the level of cortisol in the blood and the development of iatrogenic Cushing’s syndrome. These changes disappear after cessation of treatment. Adrenal cortical function should be regularly monitored by measuring cortisol levels in the blood and urine after stimulation of the adrenal glands with ACTH.

If an infection develops in the area where the drug is applied, appropriate antibacterial or antifungal treatment should be prescribed. If symptoms of infection do not go away, you should stop using Cloveit until the infection is completely cured.

You should avoid applying the drug to the skin in the eyelid area in patients with closed- or open-angle glaucoma, with cataracts due to the risk of exacerbation of the disease. On the skin of the face, in the axillary and groin areas, the drug should be used only in cases of special need, taking into account increased absorption and an increased risk of side effects (telangiectasia, perioral dermatitis).

Use with caution in atrophic conditions of subcutaneous fat, especially in the elderly.

Cloveit may enhance the effect of immunosuppressants and weaken the effect of immunostimulating drugs.

Active ingredient

Clobetasol

Composition

1 g of cream contains:

Active substances:

clobetasol propionate 500 mcg.

Auxiliary ingredients:

white petroleum jelly – 252 mg;

propylene glycol – 100 mg;

polysorbate 40 – 53 mg;

disodium edetate – 0.2 mg;

chlorocresol – 1 mg;

glyceryl monostearate – 31 mg;

liquid paraffin – 23 mg;

cetostearyl alcohol (cetyl alcohol and stearyl alcohol in a ratio of 6:4) – 69 mg;

triglycerides of octanoic and decanoic acids – 15 mg;

sodium citrate – 0.5 mg;

colloidal silicon dioxide – 1 mg;

citric acid – 0.5 mg;

flavor Hemoderm 841 – 0.3 mg;

purified water – up to 1000 mg.

Contraindications

acne vulgaris;
rosacea;
nodular prurigo Hyde;
perioral dermatitis;
skin cancer;
perianal and genital itching;
skin manifestations of syphilis;
diaper rash;
bacterial, viral and fungal skin diseases (including herpes simplex, chicken pox, skin tuberculosis, actinomycosis);
widespread plaque and pustular psoriasis;
age up to 1 year;
pregnancy;
lactation period;
hypersensitivity to the components of the drug Cloveit.

Side Effects

Local reactions: acne, steroid purpura, inhibition of epidermal growth, subcutaneous tissue atrophy, dry skin, hypertrichosis or alopecia, hypo- or hyperpigmentation of the skin, skin atrophy and striae, telangiectasia, perioral dermatitis, inflammation of the hair follicles, secondary infection.

Systemic effect: edema, arterial hypertension, decreased resistance (resorptive effect when used under an occlusive dressing).

Allergic reactions: rarely – urticaria or maculopapular rash.

From the senses: glaucoma, cataracts (when used on the skin of the eyelids).

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Pharmaceutical plant Elfa A.O., Poland